HEALTHCONN CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.35 TWD | +3.80% |
|
+5.19% | -4.04% |
| 2023 | Healthconn Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Healthconn Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2021 | 1.36B 41.84M 3.49B | Sales 2022 | 1.55B 47.43M 3.96B | Capitalization | 1.58B 48.65M 4.06B |
|---|---|---|---|---|---|
| Net income 2021 | 37M 1.14M 94.71M | Net income 2022 | 25M 767K 63.99M | EV / Sales 2021 | 1.3 x |
| Net cash position 2021 | 397M 12.19M 1.02B | Net cash position 2022 | 483M 14.83M 1.24B | EV / Sales 2022 | 0.71 x |
| P/E ratio 2021 |
58
x | P/E ratio 2022 |
62.4
x | Employees | - |
| Yield 2021 |
1.47% | Yield 2022 |
1.3% | Free-Float | 58.79% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.80% | ||
| 1 week | +5.19% | ||
| Current month | -0.36% | ||
| 1 month | -4.54% | ||
| 3 months | +5.39% | ||
| 6 months | -11.63% | ||
| Current year | -4.04% |
1 week
25.35
27.35
1 month
25.0528.20
Current year
24.8531.25
1 year
24.8542.55
3 years
24.8561.70
5 years
24.85173.00
10 years
24.85247.02
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Lun Lin
CEO | Chief Executive Officer | - | - |
Pei I Lien
DFI | Director of Finance/CFO | - | - |
Ching Hsiu Hung
IRO | Public Communications Contact | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jui Hsia Wan
BRD | Director/Board Member | - | 30/14/30 |
Kan Jen Tsai
BRD | Director/Board Member | - | 27/17/27 |
Ming Che Hsieh
BRD | Director/Board Member | - | 27/17/27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 27.35 | +3.80% | 61,971 |
| 25/24/25 | 26.35 | +1.15% | 29,450 |
| 24/24/24 | 26.05 | +0.39% | 12,590 |
| 23/24/23 | 25.95 | -0.19% | 14,143 |
| 22/24/22 | 26 | 0.00% | 101,960 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
HEALTHCONN CORP. is a Taiwan-based Company mainly engaged in the provision of disease prevention and treatment services. The Company is engaged in the provision of precisely prevent medical integration services, molecular biology testing programs and accurate diagnostic testing services. The precisely prevent medical integration services include precisely prevention, disease management and health promotion services. The molecular bioassay services include food safety testing and functional medical testing services. The accurate diagnostic testing services include molecular testing and clinical microbiological testing services, as well as the development and operation of medical health institutions. The Company is also engaged in the medical equipment sale business. The Company operates in the Taiwan market as well as in the mainland China market.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.04% | 38.02M | |
| +13.93% | 198M | |
| +26.13% | 77.74M | |
| +20.48% | 65.76M |
- Stock Market
- Equities
- 6665 Stock
